Ryvu Therapeutics SA
WSE:RVU
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| CL |
|
Sociedad Quimica y Minera de Chile SA
NYSE:SQM
|
Chemicals
|
| US |
|
General Motors Co
NYSE:GM
|
Automobiles
|
| US |
|
HP Inc
NYSE:HPQ
|
Technology
|
| US |
|
CVS Health Corp
NYSE:CVS
|
Health Care
|
| US |
|
General Electric Co
NYSE:GE
|
Industrial Conglomerates
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Procter & Gamble Co
NYSE:PG
|
Consumer products
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
39.7
64.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Sociedad Quimica y Minera de Chile SA
NYSE:SQM
|
CL |
|
|
General Motors Co
NYSE:GM
|
US |
|
|
HP Inc
NYSE:HPQ
|
US |
|
|
CVS Health Corp
NYSE:CVS
|
US |
|
|
General Electric Co
NYSE:GE
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Procter & Gamble Co
NYSE:PG
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Ryvu Therapeutics SA
Total Current Assets
Ryvu Therapeutics SA
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Total Current Assets
zł295.8m
|
CAGR 3-Years
41%
|
CAGR 5-Years
10%
|
CAGR 10-Years
33%
|
|
|
I
|
Inno-Gene SA
WSE:IGN
|
Total Current Assets
zł3m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Total Current Assets
zł2.3m
|
CAGR 3-Years
80%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
S
|
Selvita SA
WSE:SLV
|
Total Current Assets
zł120m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ryvu Therapeutics SA
Glance View
Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.
See Also
What is Ryvu Therapeutics SA's Total Current Assets?
Total Current Assets
295.8m
PLN
Based on the financial report for Sep 30, 2024, Ryvu Therapeutics SA's Total Current Assets amounts to 295.8m PLN.
What is Ryvu Therapeutics SA's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
33%
Over the last year, the Total Current Assets growth was -7%. The average annual Total Current Assets growth rates for Ryvu Therapeutics SA have been 41% over the past three years , 10% over the past five years , and 33% over the past ten years .
You don't have any saved screeners yet
